Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)Business Wire • 11/02/23
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 TrialBusiness Wire • 10/22/23
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023GlobeNewsWire • 10/17/23
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)GlobeNewsWire • 09/25/23
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)Business Wire • 09/25/23
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment resultsMarket Watch • 09/05/23
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyBusiness Wire • 09/04/23
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneBusiness Wire • 09/04/23
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Business Wire • 07/21/23
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023GlobeNewsWire • 07/20/23